[{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"b91c94f1-41f7-4fe2-83f9-441496a86f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919537","created_at":"2023-06-26T14:09:25.129Z","updated_at":"2025-02-25T15:13:34.765Z","phase":"Phase 1","brief_title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","source_id_and_acronym":"NCT05919537","lead_sponsor":"Hummingbird Bioscience","biomarkers":" ERBB3 • NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["ERBB3 • NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • albumin-bound paclitaxel • HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-13"},{"id":"5f952e53-c94e-4072-b418-d6bed213f5a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02273362","created_at":"2021-01-18T10:41:42.315Z","updated_at":"2024-07-02T16:35:12.899Z","phase":"Phase 1/2","brief_title":"Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver","source_id_and_acronym":"NCT02273362","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • EGF • PCNA","pipe":" | ","alterations":" EGFR positive","tags":["EGFR • EGF • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/24/2014","start_date":" 11/24/2014","primary_txt":" Primary completion: 02/11/2020","primary_completion_date":" 02/11/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2024-03-26"},{"id":"ca0f34fe-4463-40c0-8cfa-8c6a152a2f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390724","created_at":"2021-01-18T21:11:30.759Z","updated_at":"2024-07-02T16:35:36.823Z","phase":"","brief_title":"Optimizing Y90 Therapy for Radiation Lobectomy","source_id_and_acronym":"NCT04390724","lead_sponsor":"Northwestern University","biomarkers":" IL6 • HGF • TNFA • EGF","pipe":"","alterations":" ","tags":["IL6 • HGF • TNFA • EGF"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-09-15"},{"id":"d4e4da76-cef2-4f4b-85c3-8bdc313c9afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05107193","created_at":"2021-11-04T16:57:15.683Z","updated_at":"2024-07-02T16:36:00.743Z","phase":"","brief_title":"Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)","source_id_and_acronym":"NCT05107193","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-11-08"},{"id":"3fe819ea-51da-4422-9467-960a5f22ce0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02747953","created_at":"2021-01-18T13:27:46.249Z","updated_at":"2024-07-02T16:36:33.065Z","phase":"Phase 2","brief_title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","source_id_and_acronym":"NCT02747953","lead_sponsor":"Samsung Medical Center","biomarkers":" EGF","pipe":"","alterations":" ","tags":["EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Gilotrif (afatinib) • gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2021-03-19"}]